This is where I'm at with this company. If the DOJ/FDA was not involved in investigating this comapny, my price point for USRM by this year was around 0.07 to 0.35 cents per share, with the financials coming out the way they were, decreasing debt,and opening more clinics. I believe that was a conservative number on my part, especially comparing other companies and they're financials as well as expected growth. Now what we have is a company that is not flying under the radar, and is really stirring the pot. I love what this company is doing from a personal level, allowing people to use their own cells to heal their bodies and not be reliant on pharmaceuticals to treat their conditions. I personally work in the medical field and these treatments are so promising for patients that I had to get in on this. On the other hand from an investor's standpoint this investigation is not good for business. Yes it puts publicity and eyes on the company, but we don't have the war chest to be in a prolonged investigation and fight this in the court system. I looked over similar companies that offered these treatments that the FDA went after and it did not turn out well for the companies. They ended up having to leave the U.S. to continue business. They tried arguing the same day procedure clause that all of us are hoping will win us this fight, but because the FDA sets the rules it would be like arguing with your father whose rules are to be followed in the house. I read line by line each grievance that was against USRM and to tell you it's going to be an uphill battle. We're really going to need really good lawyers to win. The guidelines are the guidelines and we broke them. For some reason if we can argue that the manipulation we do to the SVF is indeed minimal(and the jury agreeing or judge) that we got a shot at winning this, as well as proving that these treatments that are preformed are safe. We have treated over 10,000 patients and besides the blind ladies the safety profile on these treatments are immaculate. The stem cell company that had to move out of the country did not have the study that Comella led explaining the adverse reactions to such treatments, which showed basically none.So we do have a shot at winning this but I really wouldn't get my hopes up if they lost. Once they lose they will probably have to leave the country as well because they would not be able to perform these procedure, someone buys them out, or they file bankruptcy. It wouldn't be the end of the company but we would be starting from square one. Now if they do win there would be absolutely no interference with the government, and that's when things will get interesting. By the end of this year they could reach a 20 million market cap, and it would exponentially go up from there. Once we have the funds we could finally afford to get these treatments on the fda pipeline,and get them approved. It takes millions and millions of dollars for approval. Once these things get approved insurance would follow suit. That's when the money really would flow in. I really hope that USRM sets a good argument, because this case is the single most important moment for the company since developing SVF, and hope they don't take this lightly.We have a chance, highly unlikely, but it's there.
-RainMaker3 out
